RT Journal Article
T1 Clinical Effectiveness of SARS-CoV-2 vaccination in Renal Transplant Recipients.  Antibodies levels impact in pneumonia and death.
A1 Rodriguez Cubillo, B
A1 Moreno de la Higuera M. Angeles, 
A1 Pérez Flores, Isabel María
A1 Calvo Romero, Natividad
A1 Aiffil, Arianne Sofía
A1 Arribi Vilela, Ana
A1 Peix, Belen
A1 Huertas, Sara
A1 Juez, Almudena
A1 Sánchez Fructuoso, Ana Isabel
AB Background. Few studies have described the clinical impact of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in renal transplant recipients (RTRs) in the context of omicron variant and the third vaccine dose. Antibody titer has been tried to relate to the prediction of outcomes related to SARS-CoV-2, but it results controversially in these populations.Methods. All patients with positive SARS-CoV-2 polymerase chain reaction followed at a RTRs reference center from March 15, 2020, to March 15, 2022, were considered for analysis. Cases were analyzed by vaccination status. Breakthrough cases were then analyzed by nonantibodies (<20 arbitrary unit [AU]/mL), low (20–100 AU/mL), and high antibody titers (>100 AU/mL) against SARS-CoV-2 spike protein. Outcomes included pneumonia and mortality. We used logistic regression multivariable to assess for confounders.Results. Among 186 RTRs with coronavirus disease 2019, 50.5% (n = 94) were vaccinated versus 49.5% (n = 92) unvaccinated. Of the vaccinated patients, 67.02% developed a high antibody titer (>100 AU/mL) but 14.89% achieved a low antibody titer and 18.08%. Pneumonia-free survival (day 20) was 95% in high antibody titer but 40% in unvaccinated RTRs. Survival in RTRs at day 60 was similar in the unvaccinated group compared with nonantibodies breakthrough cases (82%) but 92% in the low antibody titer group (relative risk, 0.027; 95% confidence interval, 0.002-0.479; P = 0.014). Only patients with >100 AU/mL showed a 100% survival on day 60 postinfection.Conclusions. Vaccinated RTRs who achieve at least a low antibody titer (>20 AU/mL) had better results in terms of pneumonia and mortality than unvaccinated RTRs. Antibody titer >100 AU/mL associate with even better results than patients with lower antibody titers.
PB Lippincott, Williams & Wilkins
YR 2022
FD 2022-11-01
LK https://hdl.handle.net/20.500.14352/128593
UL https://hdl.handle.net/20.500.14352/128593
LA eng
NO «Clinical Effectiveness of SARS-CoV-2 Vaccination in Renal Transplant Recipients. Antibody Levels Impact in Pneumonia and Death: Erratum». Transplantation, vol. 106, n.o 12, diciembre de 2022, pp. e529 https://doi.org/10.1097/TP.0000000000004410.
DS Docta Complutense
RD 23 mar 2026